HEADER CHAPERONE 21-JUN-10 2XHR TITLE STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N-TERMINAL DOMAIN (9-236); COMPND 5 SYNONYM: HSP 86, RENAL CARCINOMA ANTIGEN NY-REN-38; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: HSP90, HSP90A, HSP90AA1, HSPC1, HSPCA; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) KEYWDS CHAPERONE, ATP BINDING DOMAIN, N-TERMINAL DOMAIN, STRESS RESPONSE EXPDTA X-RAY DIFFRACTION AUTHOR C.W.MURRAY,M.G.CARR,O.CALLAGHAN,G.CHESSARI,M.CONGREVE,S.COWAN, AUTHOR 2 J.E.COYLE,R.DOWNHAM,E.FIGUEROA,M.FREDERICKSON,B.GRAHAM,R.MCMENAMIN, AUTHOR 3 M.A.OBRIEN,S.PATEL,T.R.PHILLIPS,G.WILLIAMS,A.J.WOODHEAD, AUTHOR 4 A.J.A.WOOLFORD REVDAT 2 08-MAY-24 2XHR 1 REMARK REVDAT 1 01-SEP-10 2XHR 0 JRNL AUTH C.W.MURRAY,M.G.CARR,O.CALLAGHAN,G.CHESSARI,M.CONGREVE, JRNL AUTH 2 S.COWAN,J.E.COYLE,R.DOWNHAM,E.FIGUEROA,M.FREDERICKSON, JRNL AUTH 3 B.GRAHAM,R.MCMENAMIN,M.A.O'BRIEN,S.PATEL,T.R.PHILLIPS, JRNL AUTH 4 G.WILLIAMS,A.J.WOODHEAD,A.J.A.WOOLFORD JRNL TITL FRAGMENT-BASED DRUG DISCOVERY APPLIED TO HSP90. DISCOVERY OF JRNL TITL 2 TWO LEAD SERIES WITH HIGH LIGAND EFFICIENCY. JRNL REF J.MED.CHEM. V. 53 5942 2010 JRNL REFN ISSN 0022-2623 JRNL PMID 20718493 JRNL DOI 10.1021/JM100059D REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER-TNT 2.5.1 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SMART,VONRHEIN,WOMACK, REMARK 3 : MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 36.20 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 3 NUMBER OF REFLECTIONS : 15070 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.253 REMARK 3 R VALUE (WORKING SET) : 0.251 REMARK 3 FREE R VALUE : 0.304 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 754 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 9 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.33 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.97 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2378 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2737 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2252 REMARK 3 BIN R VALUE (WORKING SET) : 0.2717 REMARK 3 BIN FREE R VALUE : 0.3127 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.30 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 126 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1635 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 25 REMARK 3 SOLVENT ATOMS : 78 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 52.39 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 51.83 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 7.76473 REMARK 3 B22 (A**2) : -9.19236 REMARK 3 B33 (A**2) : 1.42762 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : NULL REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : NULL REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : NULL REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : NULL ; NULL ; NULL REMARK 3 BOND ANGLES : NULL ; NULL ; NULL REMARK 3 TORSION ANGLES : NULL ; NULL ; NULL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : NULL ; NULL ; NULL REMARK 3 ISOTROPIC THERMAL FACTORS : NULL ; NULL ; NULL REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : NULL ; NULL ; NULL REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : NULL ; NULL ; NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : NULL REMARK 3 OTHER TORSION ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2XHR COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 21-JUN-10. REMARK 100 THE DEPOSITION ID IS D_1290044317. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54718 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15199 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 36.190 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : 2.500 REMARK 200 R MERGE (I) : 0.10000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 52.82 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.61 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X,Y,-Z REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z+1/2 REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 32.82600 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 44.77950 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 49.59050 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 32.82600 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 44.77950 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 49.59050 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 32.82600 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 44.77950 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 49.59050 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 32.82600 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 44.77950 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 49.59050 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -12 REMARK 465 GLY A -11 REMARK 465 SER A -10 REMARK 465 SER A -9 REMARK 465 HIS A -8 REMARK 465 HIS A -7 REMARK 465 HIS A -6 REMARK 465 HIS A -5 REMARK 465 HIS A -4 REMARK 465 HIS A -3 REMARK 465 SER A -2 REMARK 465 SER A -1 REMARK 465 GLY A 0 REMARK 465 LEU A 1 REMARK 465 VAL A 2 REMARK 465 PRO A 3 REMARK 465 ARG A 4 REMARK 465 GLY A 5 REMARK 465 SER A 6 REMARK 465 HIS A 7 REMARK 465 MET A 8 REMARK 465 ASP A 9 REMARK 465 GLN A 10 REMARK 465 PRO A 11 REMARK 465 MET A 12 REMARK 465 GLU A 13 REMARK 465 GLU A 14 REMARK 465 GLU A 15 REMARK 465 GLU A 16 REMARK 465 GLU A 225 REMARK 465 ARG A 226 REMARK 465 ASP A 227 REMARK 465 LYS A 228 REMARK 465 GLU A 229 REMARK 465 VAL A 230 REMARK 465 SER A 231 REMARK 465 ASP A 232 REMARK 465 ASP A 233 REMARK 465 GLU A 234 REMARK 465 ALA A 235 REMARK 465 GLU A 236 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO A 67 C - N - CD ANGL. DEV. = -22.3 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 62 -10.26 -47.93 REMARK 500 THR A 65 41.76 -90.66 REMARK 500 ASP A 66 103.18 153.40 REMARK 500 ASN A 106 -81.70 -50.15 REMARK 500 THR A 109 -50.85 -132.14 REMARK 500 ALA A 124 17.64 173.58 REMARK 500 ALA A 166 -145.69 67.70 REMARK 500 ARG A 182 129.95 -172.50 REMARK 500 PHE A 213 62.91 -110.05 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE C0P A 1001 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2CDD RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO- BENZOL(1,4)DIOXIN-6-YL)-5- REMARK 900 METHYL-1H- PYRAZOL-3-YL)-6-ETHYL-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN " CONFORMATION REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] DIOXOL-,5-YLMETHYL-9-BUTYL-9H- REMARK 900 PURIN-6- YLAMINE REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY- 17-N,N- REMARK 900 DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3- TRIMETHOXY-BENZYL)-9H-PURIN- REMARK 900 6YLAMINE REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN PHOSPHATASE 5 IN REMARK 900 COMPLEX WITH HSP90 DERIVED PEPTIDE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY REMARK 900 NOVEL, SYNTHETIC , POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE REMARK 900 ANALOGS REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, " CLOSED" CONFORMATION REMARK 900 RELATED ID: 2XDU RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9H-PURIN- REMARK 900 6-YLAMINE REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- METHANESULPHONYL-BENZYL)- REMARK 900 PIERAZIN-1-YL)-1H- PYRAZOL-3-YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2XDS RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN- 1-YL-1H-PYRAZOL-3-YL)- REMARK 900 BENZENE-1,2-DIOL REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, 5-TRIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9-PENT-4- YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9-PENT-9H- REMARK 900 PURIN-6- YLAMINE REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2- CHLORO-3,4,5-TRIMETHOXY-BENZYL) REMARK 900 -9H-PURIN- 6-YLAMINE REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- 4-CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2XDL RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4, 5-TRIMETHOXY-BENZYL)-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN LIGASE REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H71 REMARK 900 RELATED ID: 2XDK RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- DIMETHOXY-BENZYL)-2-FLUORO- REMARK 900 9H-PURIN-6- YLAMINE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] DIOXOL-,5-YLMETHYL-9-BUTYL-2- REMARK 900 FLUORO-9H- PURIN-6-YLAMINE REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4- DIHYDROXY-PHENYL)-4-PIPERAZIN-1- REMARK 900 YL-2H- PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H64 REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE- BASED INHIBITOR BINDING REMARK 900 TO HSP90 ISOFORMS REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, 5-TRIMETHOXY-BENZYL)-9-PENT- REMARK 900 4-YLNYL-9H- PURIN-6-YLAMINE REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2XAB RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2XHT RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- DIMETHOXY-BENZYL)-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4- METHOXY-BENZYL)-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN- BINDING DOMAIN REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- 4-CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE DBREF 2XHR A 9 236 UNP P07900 HS90A_HUMAN 9 236 SEQADV 2XHR MET A -12 UNP P07900 EXPRESSION TAG SEQADV 2XHR GLY A -11 UNP P07900 EXPRESSION TAG SEQADV 2XHR SER A -10 UNP P07900 EXPRESSION TAG SEQADV 2XHR SER A -9 UNP P07900 EXPRESSION TAG SEQADV 2XHR HIS A -8 UNP P07900 EXPRESSION TAG SEQADV 2XHR HIS A -7 UNP P07900 EXPRESSION TAG SEQADV 2XHR HIS A -6 UNP P07900 EXPRESSION TAG SEQADV 2XHR HIS A -5 UNP P07900 EXPRESSION TAG SEQADV 2XHR HIS A -4 UNP P07900 EXPRESSION TAG SEQADV 2XHR HIS A -3 UNP P07900 EXPRESSION TAG SEQADV 2XHR SER A -2 UNP P07900 EXPRESSION TAG SEQADV 2XHR SER A -1 UNP P07900 EXPRESSION TAG SEQADV 2XHR GLY A 0 UNP P07900 EXPRESSION TAG SEQADV 2XHR LEU A 1 UNP P07900 EXPRESSION TAG SEQADV 2XHR VAL A 2 UNP P07900 EXPRESSION TAG SEQADV 2XHR PRO A 3 UNP P07900 EXPRESSION TAG SEQADV 2XHR ARG A 4 UNP P07900 EXPRESSION TAG SEQADV 2XHR GLY A 5 UNP P07900 EXPRESSION TAG SEQADV 2XHR SER A 6 UNP P07900 EXPRESSION TAG SEQADV 2XHR HIS A 7 UNP P07900 EXPRESSION TAG SEQADV 2XHR MET A 8 UNP P07900 EXPRESSION TAG SEQRES 1 A 249 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER GLY SEQRES 2 A 249 LEU VAL PRO ARG GLY SER HIS MET ASP GLN PRO MET GLU SEQRES 3 A 249 GLU GLU GLU VAL GLU THR PHE ALA PHE GLN ALA GLU ILE SEQRES 4 A 249 ALA GLN LEU MET SER LEU ILE ILE ASN THR PHE TYR SER SEQRES 5 A 249 ASN LYS GLU ILE PHE LEU ARG GLU LEU ILE SER ASN SER SEQRES 6 A 249 SER ASP ALA LEU ASP LYS ILE ARG TYR GLU SER LEU THR SEQRES 7 A 249 ASP PRO SER LYS LEU ASP SER GLY LYS GLU LEU HIS ILE SEQRES 8 A 249 ASN LEU ILE PRO ASN LYS GLN ASP ARG THR LEU THR ILE SEQRES 9 A 249 VAL ASP THR GLY ILE GLY MET THR LYS ALA ASP LEU ILE SEQRES 10 A 249 ASN ASN LEU GLY THR ILE ALA LYS SER GLY THR LYS ALA SEQRES 11 A 249 PHE MET GLU ALA LEU GLN ALA GLY ALA ASP ILE SER MET SEQRES 12 A 249 ILE GLY GLN PHE GLY VAL GLY PHE TYR SER ALA TYR LEU SEQRES 13 A 249 VAL ALA GLU LYS VAL THR VAL ILE THR LYS HIS ASN ASP SEQRES 14 A 249 ASP GLU GLN TYR ALA TRP GLU SER SER ALA GLY GLY SER SEQRES 15 A 249 PHE THR VAL ARG THR ASP THR GLY GLU PRO MET GLY ARG SEQRES 16 A 249 GLY THR LYS VAL ILE LEU HIS LEU LYS GLU ASP GLN THR SEQRES 17 A 249 GLU TYR LEU GLU GLU ARG ARG ILE LYS GLU ILE VAL LYS SEQRES 18 A 249 LYS HIS SER GLN PHE ILE GLY TYR PRO ILE THR LEU PHE SEQRES 19 A 249 VAL GLU LYS GLU ARG ASP LYS GLU VAL SER ASP ASP GLU SEQRES 20 A 249 ALA GLU HET C0P A1001 25 HETNAM C0P 4-CHLORO-6-[2,4-DICHLORO-5-(2-MORPHOLIN-4-YLETHOXY) HETNAM 2 C0P PHENYL]PYRIMIDIN-2-AMINE FORMUL 2 C0P C16 H17 CL3 N4 O2 FORMUL 3 HOH *78(H2 O) HELIX 1 1 GLN A 23 THR A 36 1 14 HELIX 2 2 GLU A 42 GLU A 62 1 21 HELIX 3 3 ASP A 66 GLY A 73 5 8 HELIX 4 4 THR A 99 THR A 109 1 11 HELIX 5 5 ALA A 111 GLN A 123 1 13 HELIX 6 6 ASP A 127 GLY A 135 5 9 HELIX 7 7 VAL A 136 LEU A 143 5 8 HELIX 8 8 GLU A 192 LEU A 198 5 7 HELIX 9 9 GLU A 199 SER A 211 1 13 SHEET 1 AA 8 GLU A 18 ALA A 21 0 SHEET 2 AA 8 SER A 169 THR A 174 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 TYR A 160 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 LYS A 153 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 GLY A 183 LEU A 190 -1 O GLY A 183 N LYS A 153 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 SITE 1 AC1 14 SER A 52 ALA A 55 ASP A 93 GLY A 97 SITE 2 AC1 14 MET A 98 ASN A 106 LEU A 107 ILE A 110 SITE 3 AC1 14 GLY A 135 PHE A 138 THR A 184 HOH A2013 SITE 4 AC1 14 HOH A2058 HOH A2078 CRYST1 65.652 89.559 99.181 90.00 90.00 90.00 I 2 2 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015232 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011166 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010083 0.00000 TER 1636 LYS A 224 HETATM 1637 N1 C0P A1001 -3.664 11.553 23.781 1.00 35.08 N HETATM 1638 C2 C0P A1001 -2.692 11.143 24.633 1.00 39.21 C HETATM 1639 N3 C0P A1001 -3.086 10.651 25.823 1.00 48.61 N HETATM 1640 C4 C0P A1001 -2.098 10.275 26.635 1.00 53.82 C HETATM 1641 CL5 C0P A1001 -2.560 9.623 28.169 1.00 63.35 CL HETATM 1642 C6 C0P A1001 -0.773 10.354 26.310 1.00 52.15 C HETATM 1643 C7 C0P A1001 -0.444 10.873 25.080 1.00 46.15 C HETATM 1644 N8 C0P A1001 -1.396 11.283 24.229 1.00 40.08 N HETATM 1645 C9 C0P A1001 0.977 11.021 24.661 1.00 42.10 C HETATM 1646 C10 C0P A1001 1.751 9.861 24.546 1.00 40.34 C HETATM 1647 C11 C0P A1001 3.098 9.929 24.190 1.00 43.77 C HETATM 1648 O12 C0P A1001 3.904 8.836 24.035 1.00 51.37 O HETATM 1649 C13 C0P A1001 3.343 7.543 24.354 1.00 55.12 C HETATM 1650 C14 C0P A1001 4.380 6.501 24.037 1.00 59.47 C HETATM 1651 N15 C0P A1001 5.568 6.555 24.960 1.00 57.03 N HETATM 1652 C17 C0P A1001 5.155 6.620 26.398 1.00 51.17 C HETATM 1653 C18 C0P A1001 6.389 6.682 27.287 1.00 61.30 C HETATM 1654 O19 C0P A1001 7.243 7.792 26.943 1.00 61.47 O HETATM 1655 C20 C0P A1001 7.669 7.695 25.575 1.00 64.38 C HETATM 1656 C21 C0P A1001 6.484 7.696 24.624 1.00 60.30 C HETATM 1657 C22 C0P A1001 3.711 11.189 24.006 1.00 44.25 C HETATM 1658 CL23 C0P A1001 5.401 11.318 23.597 1.00 46.70 CL HETATM 1659 C24 C0P A1001 2.970 12.349 24.153 1.00 43.34 C HETATM 1660 C25 C0P A1001 1.620 12.276 24.489 1.00 42.43 C HETATM 1661 CL26 C0P A1001 0.736 13.756 24.657 1.00 46.54 CL HETATM 1662 O HOH A2001 12.592 26.161 35.726 1.00 39.86 O HETATM 1663 O HOH A2002 10.915 28.864 29.932 1.00 39.66 O HETATM 1664 O HOH A2003 10.928 28.582 34.141 1.00 50.64 O HETATM 1665 O HOH A2004 10.302 28.493 27.278 1.00 51.65 O HETATM 1666 O HOH A2005 23.285 7.089 23.406 1.00 56.92 O HETATM 1667 O HOH A2006 15.500 20.303 18.886 1.00 40.24 O HETATM 1668 O HOH A2007 8.685 19.988 9.069 1.00 43.21 O HETATM 1669 O HOH A2008 8.901 19.937 4.298 1.00 47.60 O HETATM 1670 O HOH A2009 -3.007 13.628 0.468 1.00 47.12 O HETATM 1671 O HOH A2010 1.129 7.515 17.287 1.00 48.34 O HETATM 1672 O HOH A2011 3.602 5.682 11.814 1.00 46.53 O HETATM 1673 O HOH A2012 -1.319 7.469 23.916 1.00 48.82 O HETATM 1674 O HOH A2013 -0.707 12.457 21.522 1.00 35.45 O HETATM 1675 O HOH A2014 -5.656 1.900 20.153 1.00 50.72 O HETATM 1676 O HOH A2015 0.194 5.231 19.268 1.00 48.61 O HETATM 1677 O HOH A2016 0.518 5.653 22.704 1.00 50.84 O HETATM 1678 O HOH A2017 -3.281 0.869 25.272 1.00 43.10 O HETATM 1679 O HOH A2018 -9.457 -0.127 20.259 1.00 52.04 O HETATM 1680 O HOH A2019 -11.608 -1.251 20.747 1.00 57.78 O HETATM 1681 O HOH A2020 -10.040 -3.479 26.954 1.00 59.58 O HETATM 1682 O HOH A2021 -7.036 -7.483 39.192 1.00 67.84 O HETATM 1683 O HOH A2022 -13.661 12.772 31.287 1.00 53.70 O HETATM 1684 O HOH A2023 8.204 26.304 25.412 1.00 51.35 O HETATM 1685 O HOH A2024 -17.175 5.326 23.231 1.00 50.66 O HETATM 1686 O HOH A2025 -14.282 18.607 23.819 1.00 39.05 O HETATM 1687 O HOH A2026 -18.664 15.290 21.694 1.00 48.16 O HETATM 1688 O HOH A2027 -8.574 24.370 18.379 1.00 35.08 O HETATM 1689 O HOH A2028 -14.030 25.943 17.019 1.00 39.68 O HETATM 1690 O HOH A2029 -12.931 26.492 18.860 1.00 42.66 O HETATM 1691 O HOH A2030 -9.935 25.816 19.809 1.00 49.26 O HETATM 1692 O HOH A2031 -7.640 21.545 1.833 1.00 51.86 O HETATM 1693 O HOH A2032 -21.276 18.638 10.604 1.00 50.90 O HETATM 1694 O HOH A2033 -15.774 34.892 16.207 1.00 60.56 O HETATM 1695 O HOH A2034 -7.624 27.592 20.692 1.00 41.43 O HETATM 1696 O HOH A2035 -5.239 14.172 22.589 1.00 36.26 O HETATM 1697 O HOH A2036 -10.828 15.474 27.819 1.00 46.65 O HETATM 1698 O HOH A2037 -7.195 8.816 34.734 1.00 45.46 O HETATM 1699 O HOH A2038 -2.725 14.700 35.702 1.00 44.76 O HETATM 1700 O HOH A2039 3.653 21.366 41.465 1.00 52.61 O HETATM 1701 O HOH A2040 10.736 5.742 23.668 1.00 54.36 O HETATM 1702 O HOH A2041 17.495 -0.129 17.933 1.00 56.79 O HETATM 1703 O HOH A2042 1.894 3.936 18.046 1.00 56.67 O HETATM 1704 O HOH A2043 3.368 6.647 18.839 1.00 49.53 O HETATM 1705 O HOH A2044 3.719 9.117 20.803 1.00 41.29 O HETATM 1706 O HOH A2045 9.084 26.227 16.657 1.00 50.02 O HETATM 1707 O HOH A2046 -6.831 6.041 36.759 1.00 50.45 O HETATM 1708 O HOH A2047 -7.393 19.338 38.451 1.00 60.46 O HETATM 1709 O HOH A2048 12.057 27.504 19.128 1.00 49.23 O HETATM 1710 O HOH A2049 10.191 25.781 23.390 1.00 43.81 O HETATM 1711 O HOH A2050 13.426 20.519 21.047 1.00 36.44 O HETATM 1712 O HOH A2051 17.642 21.624 20.205 1.00 42.36 O HETATM 1713 O HOH A2052 10.576 26.126 26.712 1.00 39.02 O HETATM 1714 O HOH A2053 3.631 24.848 30.410 1.00 37.75 O HETATM 1715 O HOH A2054 6.255 26.861 27.321 1.00 43.03 O HETATM 1716 O HOH A2055 2.240 26.366 38.487 1.00 60.26 O HETATM 1717 O HOH A2056 -1.298 26.924 31.967 1.00 48.96 O HETATM 1718 O HOH A2057 -9.624 12.847 36.587 1.00 41.08 O HETATM 1719 O HOH A2058 -5.220 10.682 27.660 1.00 33.47 O HETATM 1720 O HOH A2059 -8.598 23.349 29.189 1.00 55.38 O HETATM 1721 O HOH A2060 0.747 20.436 4.444 1.00 52.24 O HETATM 1722 O HOH A2061 -7.910 27.266 6.570 1.00 52.08 O HETATM 1723 O HOH A2062 0.082 16.457 3.171 1.00 45.37 O HETATM 1724 O HOH A2063 -10.692 23.329 1.719 1.00 63.94 O HETATM 1725 O HOH A2064 -14.188 24.527 7.273 1.00 42.45 O HETATM 1726 O HOH A2065 -18.375 17.839 10.892 1.00 59.06 O HETATM 1727 O HOH A2066 -14.203 22.810 4.076 1.00 54.22 O HETATM 1728 O HOH A2067 -16.790 18.066 3.671 1.00 57.06 O HETATM 1729 O HOH A2068 -5.922 12.843 -0.677 1.00 51.74 O HETATM 1730 O HOH A2069 -5.453 7.160 13.675 1.00 45.14 O HETATM 1731 O HOH A2070 -17.843 4.534 12.825 1.00 55.09 O HETATM 1732 O HOH A2071 -9.510 2.215 18.217 1.00 54.46 O HETATM 1733 O HOH A2072 -16.446 2.854 21.617 1.00 53.22 O HETATM 1734 O HOH A2073 -16.695 12.370 19.704 1.00 44.30 O HETATM 1735 O HOH A2074 -18.082 14.360 13.031 1.00 40.79 O HETATM 1736 O HOH A2075 -14.885 22.019 10.887 1.00 46.76 O HETATM 1737 O HOH A2076 -16.505 24.814 16.901 1.00 42.48 O HETATM 1738 O HOH A2077 -18.360 28.566 18.847 1.00 45.85 O HETATM 1739 O HOH A2078 -3.401 12.946 21.270 1.00 33.88 O CONECT 1637 1638 CONECT 1638 1637 1639 1644 CONECT 1639 1638 1640 CONECT 1640 1639 1641 1642 CONECT 1641 1640 CONECT 1642 1640 1643 CONECT 1643 1642 1644 1645 CONECT 1644 1638 1643 CONECT 1645 1643 1646 1660 CONECT 1646 1645 1647 CONECT 1647 1646 1648 1657 CONECT 1648 1647 1649 CONECT 1649 1648 1650 CONECT 1650 1649 1651 CONECT 1651 1650 1652 1656 CONECT 1652 1651 1653 CONECT 1653 1652 1654 CONECT 1654 1653 1655 CONECT 1655 1654 1656 CONECT 1656 1651 1655 CONECT 1657 1647 1658 1659 CONECT 1658 1657 CONECT 1659 1657 1660 CONECT 1660 1645 1659 1661 CONECT 1661 1660 MASTER 471 0 1 9 8 0 4 6 1738 1 25 20 END